Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Novella Pugliese et al.|Cancer|2024Cited by 10
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Filíppo Gherlinzoni, Francesca Palandri et al.|Cancer|2025Cited by 10
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalentMichele Baccarani, Francesco Passamonti, Ilaria Iacobucci et al.|Leukemia|2019Cited by 9
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Andrew Kuykendall, Filippo Branzanti et al.|Cancer|2025Cited by 5
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Elisabetta Abruzzese, Massimo Breccia et al.|Leukemia Research|2025Cited by 4